About Roivant Sciences
Roivant Sciences is a company based in New York (United States) founded in 2014 by Vivek Ramaswamy.. Roivant Sciences has raised $1.3 billion across 4 funding rounds from investors including HHS, RTW Investments and SoftBank Vision Fund. The company has 750 employees as of March 31, 2024. Roivant Sciences has completed 2 acquisitions, including Plexcera Therapeutics and Silicon Therapeutics. Roivant Sciences offers products and services including Vants, Immunovant, Priovant, and Pulmovant. Roivant Sciences operates in a competitive market with competitors including Merck, AbbVie, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter New York, United States
- Employees 750 as on 31 Mar, 2024
- Founders Vivek Ramaswamy
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Roivant Sciences Ltd.
-
Annual Revenue
$29.05 M-11.19as on Mar 31, 2024
-
Net Profit
$-171.98 M-103.95as on Mar 31, 2024
-
EBITDA
$-1.11 B-35.86as on Mar 31, 2024
-
Total Equity Funding
$1.3 B (USD)
in 4 rounds
-
Latest Funding Round
$200 M (USD), Private Equity Round
Nov 13, 2018
-
Investors
HHS
& 5 more
-
Employee Count
750
as on Mar 31, 2024
-
Investments & Acquisitions
Plexcera Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Roivant Sciences
Roivant Sciences is a publicly listed company on the NASDAQ with ticker symbol ROIV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Roivant Sciences
Roivant Sciences offers a comprehensive portfolio of products and services, including Vants, Immunovant, Priovant, and Pulmovant. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for creating focused subsidiaries to develop medicines
Subsidiary advancing treatments for autoimmune diseases
Subsidiary targeting severe autoimmune conditions
Subsidiary focused on pulmonary disease treatments
Unlock access to complete
Unlock access to complete
Leadership Team
24 people
Finance and Accounting
11 people
Board Team
9 people
Senior Team
9 people
Software Development Team
7 people
Advisor Team
6 people
Human Resources and Administration
6 people
Head Team
5 people
Unlock access to complete
Funding Insights of Roivant Sciences
Roivant Sciences has successfully raised a total of $1.3B across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round round of $200 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Private Equity Round — $200.0M
- First Round First Round
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2018 | Amount | Private Equity Round - Roivant Sciences | Valuation | NovaQuest Capital Management | |
| Apr, 2018 | Amount | Grant - Roivant Sciences | Valuation |
investors |
|
| Aug, 2017 | Amount | Private Equity Round - Roivant Sciences | Valuation | SoftBank Vision Fund |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Roivant Sciences
Roivant Sciences has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RTW Investments and SoftBank Vision Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Founded Year | Domain | Location | |
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
PE firm focused on life science and healthcare companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Roivant Sciences
Roivant Sciences has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Plexcera Therapeutics and Silicon Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of In-Silico Targeted Engineering platform to build in silico models of human drug targets
|
2016 | ||||
|
Therapeutics for genetic diseases using recombinant acid ceramidase are developed.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Roivant Sciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Roivant Sciences Comparisons
Competitors of Roivant Sciences
Roivant Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Gilead, Lilly and Vertex Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Roivant Sciences
Frequently Asked Questions about Roivant Sciences
When was Roivant Sciences founded?
Roivant Sciences was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Roivant Sciences located?
Roivant Sciences is headquartered in New York, United States. It is registered at New York, New York, United States.
Who is the current CEO of Roivant Sciences?
Matthew Gline is the current CEO of Roivant Sciences.
Is Roivant Sciences a funded company?
Roivant Sciences is a funded company, having raised a total of $1.3B across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $1.1B, raised on Dec 01, 2015.
How many employees does Roivant Sciences have?
As of Mar 31, 2024, the latest employee count at Roivant Sciences is 750.
What is the annual revenue of Roivant Sciences?
Annual revenue of Roivant Sciences is $29.05M as on Mar 31, 2024.
What does Roivant Sciences do?
Roivant Sciences is developing therapeutics in disease areas such as neurology, oncology, rare diseases, and endocrinology. Its CNS drug pipeline include Intepirdine, a selective 5-HT6 receptor antagonist for mild-to-moderate Alzheimers disease (phase 3), dementia with Lewy bodies (DLB) (phase 3), gait and balance impairments in dementia (phase 2); Nelotanserin, agonist of the 5-HT2A receptor for visual hallucinations in Lewy body dementia (phase 2), REM behavior disorder (RBD) in DLB (phase 23); RVT-103 and RVT-104 for Alzheimers disease (phase 1) and Lewy body dementia (phase 1). Other drugs in the pipeline include Relugolix for uterine fibroids (phase 3), endometriosis (phase 3) and prostate cancer (phase 3). It is also developing drugs for atopic dermatitis (phase 2), autism (phase 2), female infertility (phase 2) and Farber disease (phase 2).
Who are the top competitors of Roivant Sciences?
What products or services does Roivant Sciences offer?
Roivant Sciences offers Vants, Immunovant, Priovant, and Pulmovant.
Is Roivant Sciences publicly traded?
Yes, Roivant Sciences is publicly traded on NASDAQ under the ticker symbol ROIV.
How many acquisitions has Roivant Sciences made?
Roivant Sciences has made 2 acquisitions, including Plexcera Therapeutics, and Silicon Therapeutics.
Who are Roivant Sciences's investors?
Roivant Sciences has 6 investors. Key investors include HHS, RTW Investments, SoftBank Vision Fund, Dexcel Pharma, and Viking Global Investors.
What is Roivant Sciences's ticker symbol?
The ticker symbol of Roivant Sciences is ROIV on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.